Antibiotic flush directly into the lungs tested against bronchiectasis Flare-Ups
NCT ID NCT07813299
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Bronchiectasis damages the airways and causes repeated flare-ups of cough and breathlessness. Researchers are testing whether washing the affected lung areas with saline through a bronchoscope, then injecting the antibiotic amikacin directly into those areas, can delay the next flare-up better than standard treatment or a saline wash alone. The trial enrolls 186 adults hospitalized with an acute bronchiectasis flare-up and compares how long each group goes before their next flare-up, along with symptom scores and lung function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- amikacin, an antibiotic, given directly into the airways during bronchoscopy after a saline lung wash
- What this could lead to
- If it works, this approach could give doctors a way to delay the next bronchiectasis flare-up and help patients stay out of hospital longer.
- What could go wrong
- Bronchoscopy is an invasive procedure with risks like bleeding, infection, or breathing problems, and the extra benefit of adding amikacin over a plain saline wash is not yet known. Results from this single trial may not apply to all patients with bronchiectasis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 186 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged between 18 and 80 years, inclusive. 2. According to the adult bronchiectasis guidelines, diagnosed with bronchiectasis, and indicating lesions accumulating in 2 or more lung lobes. 3. Presenting with an acute exacerbation, defined by worsening of key symptoms (e.g., cough, sputum volume, dyspnea, chest tightness, or wheezing), and willing to undergo bronchoscopy with bronchoalveolar lavage (BAL). 4. Patients who are alert, cooperative, and able to tolerate the bronchoscopic procedure. 5. Provided written informed consent to participate in this clinical trial. Exclusion Criteria: 1. Presence of severe comorbidities or any contraindications to flexible bronchoscopy. 2. Intraoperative oxygen desaturation (SpO₂) or inability to tolerate bronchoalveolar lavage (BAL) following bronchoscopic insertion. 3. Declined participation or was deemed ineligible by the investigator for other reasons. 4. Coagulopathy (platelet count \< 50 × 10⁹/L) or active airway bleeding observed during bronchoscopy, posing a potential risk of exacerbation from BAL. 5. Incomplete procedural documentation or missing follow-up data. 6. Known allergy or hypersensitivity to amikacin. 7. Concurrent renal failure. 8. Diagnosis of cystic fibrosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiectasis with acute exacerbation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Ningbo University
RECRUITINGNingbo, Zhejiang, 315010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.